Frazier Life Sciences Management L.P. Has $35.15 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Frazier Life Sciences Management L.P. boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,069,754 shares of the biopharmaceutical company's stock after acquiring an additional 25,600 shares during the quarter. Agios Pharmaceuticals accounts for about 1.5% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 17th biggest position. Frazier Life Sciences Management L.P. owned about 1.88% of Agios Pharmaceuticals worth $35,152,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AGIO. Venturi Wealth Management LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter valued at about $33,000. Wingate Wealth Advisors Inc. bought a new stake in Agios Pharmaceuticals in the fourth quarter valued at about $53,000. Sterling Capital Management LLC increased its stake in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after acquiring an additional 1,587 shares during the period. KBC Group NV increased its stake in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares during the period. Finally, AlphaQuest LLC grew its stake in Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after buying an additional 2,338 shares during the last quarter.

Agios Pharmaceuticals Trading Up 0.7%

Shares of AGIO traded up $0.21 during mid-day trading on Friday, hitting $29.80. 440,665 shares of the company traded hands, compared to its average volume of 695,037. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The business has a 50-day moving average of $28.66 and a 200 day moving average of $36.16. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of 2.63 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The firm had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. As a group, analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday. Finally, Scotiabank decreased their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Agios Pharmaceuticals has an average rating of "Hold" and a consensus price target of $56.00.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.30% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.